Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report

JCO Precis Oncol. 2021 May 3:5:PO.20.00534. doi: 10.1200/PO.20.00534. eCollection 2021.

Authors

Xi He¹, Xiao-Dong Jiao¹, Ke Liu¹, Bao-Dong Qin¹, Ying Wu¹, Yan Ling¹, Jun Liu¹, A-Qiao Xu², Kun Song³, Yuan-Sheng Zang¹

Affiliations

¹ Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
² Shaoxing Central Hospital, Shaoxing, Zhejiang Province, China.
³ Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Aminopyridines / therapeutic use*
Anaplastic Lymphoma Kinase / genetics
Antineoplastic Agents
Carbazoles / therapeutic use*
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics
Colorectal Neoplasms / pathology
Crizotinib / therapeutic use*
Female
Gene Rearrangement
Humans
Lactams / therapeutic use*
Neoplasm Metastasis
Piperidines / therapeutic use*
Pyrazoles / therapeutic use*
Treatment Outcome

Substances

Aminopyridines
Antineoplastic Agents
Carbazoles
Lactams
Piperidines
Pyrazoles
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
alectinib
lorlatinib